Please visit Ozempic.com or Wegovy.com for a full list of important safety information for these medications
For instance in the SCALE trials, non-completing patients typically discontinued liraglutide 3.0 mg due to tolerability issues, whereas non-completing patients typically discontinued placebo due to lack of effect, and there are no strong arguments to suggest that the patients who discontinued placebo would also have been the patients who would experience tolerability issues had they been randomized to liraglutide 3.0 mg instead
The specific reasons identified include intensive insulin therapy, decreased renal function, severe liver disease, alcohol ingestion, defective counter regulatory hormone release, missing meals/fasting, and gastroparesis
Manufacturer overfill adds 515% more peptide than labeled
Once this vial has been open, it has been exposed to air and germs